000779294 000__ 02955cam\a2200493Ii\4500
000779294 001__ 779294
000779294 005__ 20230306142922.0
000779294 006__ m\\\\\o\\d\\\\\\\\
000779294 007__ cr\nn\nnnunnun
000779294 008__ 170203s2017\\\\sz\\\\\\ob\\\\000\0\eng\d
000779294 019__ $$a981773046
000779294 020__ $$a9783034809771$$q(electronic book)
000779294 020__ $$a3034809778$$q(electronic book)
000779294 020__ $$z9783034809757
000779294 0247_ $$a10.1007/978-3-0348-0977-1$$2doi
000779294 035__ $$aSP(OCoLC)ocn971245840
000779294 035__ $$aSP(OCoLC)971245840$$z(OCoLC)981773046
000779294 040__ $$aN$T$$beng$$erda$$epn$$cN$T$$dGW5XE$$dEBLCP$$dN$T$$dIDEBK$$dYDX$$dOCLCF$$dNJR$$dUAB$$dCOO$$dIOG$$dAZU$$dUPM
000779294 049__ $$aISEA
000779294 050_4 $$aRC858.C95
000779294 08204 $$a616.3/72$$223
000779294 24500 $$aTreatment of cystic fibrosis and other rare lung diseases /$$cArata Azuma, Michael S. Schechter, editors.
000779294 264_1 $$aSwitzerland :$$bSpringer,$$c2017.
000779294 300__ $$a1 online resource.
000779294 336__ $$atext$$btxt$$2rdacontent
000779294 337__ $$acomputer$$bc$$2rdamedia
000779294 338__ $$aonline resource$$bcr$$2rdacarrier
000779294 347__ $$atext file$$bPDF$$2rda
000779294 4901_ $$aMilestones in drug therapy,$$x2296-6056
000779294 504__ $$aIncludes bibliographical references.
000779294 5050_ $$aPart I Etiopathology and Genetics of Rare Lung Diseases -- Part II Treatment of Cystic Fibrosis -- Part III Treatment of Other Rare Lung Diseases.
000779294 506__ $$aAccess limited to authorized users.
000779294 520__ $$aThis volume describes the pathogenesis and pathophysiology of several pulmonary diseases as well as their treatment. It also discusses the underlying genetic and molecular biological basis, which opens the way for new treatments for these conditions. It focuses on the treatment of cystic fibrosis including CFTR (cystic fibrosis transmembrane-conductance regulator) modulator therapies, drug therapies that augment airway surface liquid as well as anti-inflammatory and anti-infective therapies. Further topics include long-term, low-dose macrolide therapy for diffuse panbronchiolitis; novel agents for previously untreatable idiopathic pulmonary fibrosis; possible new treatments for pulmonary alveolar proteinosis (PAP); and multiple novel therapeutic targets for treating lymphangiomyomatosis. Research into these conditions has led to major advances in our understanding of the underlying genetic and molecular basis of this disease, and to dramatic improvements in survival and quality of life for affected individuals.
000779294 588__ $$aOnline resource; title from PDF title page (SpringerLink, viewed February 9, 2017).
000779294 650_0 $$aCystic fibrosis$$xTreatment.
000779294 650_0 $$aLungs$$xDiseases$$xTreatment.
000779294 7001_ $$aAzuma, Arata,$$eeditor.
000779294 7001_ $$aSchechter, Michael S.,$$eeditor.
000779294 77608 $$iPrint version:$$z9783034809757
000779294 830_0 $$aMilestones in drug therapy.
000779294 852__ $$bebk
000779294 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-0348-0977-1$$zOnline Access$$91397441.1
000779294 909CO $$ooai:library.usi.edu:779294$$pGLOBAL_SET
000779294 980__ $$aEBOOK
000779294 980__ $$aBIB
000779294 982__ $$aEbook
000779294 983__ $$aOnline
000779294 994__ $$a92$$bISE